Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 27, 2026

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

7.1K

Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein.

Debora Patricia Garanzini1, Matias Ariel Micucci2, Annalies Torres Lopez1

  • 1Instituto de Agrobiotecnología y Biología Molecular (IABiMo), Instituto Nacional de Tecnología Agropecuaria (INTA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Nicolás Repetto y De Los Reseros S/N, Hurlingham B1686IGC, Buenos Aires, Argentina.

Viruses
|April 26, 2025
PubMed
Summary

Related Concept Videos

Rabies01:28

Rabies

Rabies is a lethal zoonotic disease caused by a single-stranded, negative-sense RNA virus of the Lyssavirus genus, within the family Rhabdoviridae. Its primary mode of transmission to humans is through bites or saliva-contaminated scratches from infected mammals such as dogs, bats, raccoons, or foxes. Transmission can also occur if infectious saliva contacts abraded skin or intact mucous membranes, including the conjunctiva.Viral Entry and Early ReplicationOnce introduced at the bite or scratch...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Octanoic acid addition: a simple, affordable modification that overcomes lipid removal limitations of traditional antivenom production processes.

Biologicals : journal of the International Association of Biological Standardization·2025
Same author

Development, Implementation, Pharmacokinetic and Safety Evaluation of an Immunotherapeutic Treatment for COVID-19: Double-blind Randomized Placebo-controlled Trial.

Prague medical report·2025
Same author

Carotid Artery Stenting.

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Value-Based Interventions for Lower Extremity Peripheral Vascular Interventions.

Journal of the Society for Cardiovascular Angiography & Interventions·2024
Same author

Long-Term Patient Symptoms and Quality of Life in Adults After COVID-19: A Real Life Study.

Open respiratory archives·2024
Same author

One-Year Outcomes of Patients Requiring Tracheostomy Placement Due to Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Critical care explorations·2023
Same journal

Correction: Bulatov et al. Camelpox Virus in Western Kazakhstan: Assessment of the Role of Local Fauna as Reservoirs of Infection. <i>Viruses</i> 2024, <i>16</i>, 1626.

Viruses·2026
Same journal

Correction: Franco et al. Whole Blood Volume-Based Absolute Quantification of HTLV-1 Proviral Load: A Comparative Method Evaluation Study. <i>Viruses</i> 2026, <i>18</i>, 580.

Viruses·2026
Same journal

Correction: Medkour et al. Adenovirus Infections in African Humans and Wild Non-Human Primates: Great Diversity and Cross-Species Transmission. <i>Viruses</i> 2020, <i>12</i>, 657.

Viruses·2026
Same journal

Burden of Malaria and Dengue Across Global, Asian, and Chinese Populations Based on GBD 2021 Data: A Quantitative Assessment of Importation Risks to China.

Viruses·2026
Same journal

First Report of <i>Orthonairovirus songlingense</i> in <i>Haemaphysalis concinna</i> Ticks from Russia.

Viruses·2026
Same journal

Epidemiological and Virological Characteristics of H9N2 Avian Influenza Virus in Jiangsu Province, China, 2024.

Viruses·2026
See all related articles
This summary is machine-generated.

Two novel rabies vaccines using non-replicative viral vectors, MVA-RG and Ad-RG, showed significant protection in mice. The Ad-RG vaccine achieved 100% protection against rabies virus challenge, offering a promising new approach.

Area of Science:

  • Veterinary Virology
  • Immunology
  • Public Health

Background:

  • Rabies is a fatal zoonotic viral disease, necessitating effective vaccination strategies.
  • The "One Health" approach emphasizes controlling diseases at the animal source for human health protection.
  • Developing novel, safe, and effective anti-rabies vaccines is crucial for disease prevention.

Purpose of the Study:

  • To develop and evaluate two third-generation anti-rabies vaccines using modified vaccinia virus Ankara (MVA) and adenovirus serotype 5 (Ad5) viral vectors.
  • To assess the efficacy of these vaccines (MVA-RG and Ad-RG) in protecting mice against rabies virus (RABV) challenge.
  • To investigate the impact of viral vector, dose, and immunization scheme on vaccine-induced protection.

Main Methods:

Keywords:
Ad5MVAadenovirusglycoproteinrabiesvector-based vaccineviral vector

More Related Videos

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.3K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.1K

Related Experiment Videos

Last Updated: Jun 27, 2026

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

7.1K
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.3K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.1K
  • Development of MVA-RG vaccine using an in-house platform and Ad-RG vaccine using a commercial kit, both expressing RABV glycoprotein.
  • Administration of homologous doses of MVA-RG and Ad-RG vaccines to mice.
  • Assessment of vaccine efficacy through an intracerebral (IC) RABV challenge model in mice.

    • Main Results:

    • Both MVA-RG and Ad-RG vaccines conferred protection against RABV challenge.
    • MVA-RG demonstrated 60% protection, while Ad-RG showed 60-100% protection in mice.
    • The study reports, for the first time, 100% protection against IC RABV challenge using a non-replicative Ad5 vector in a homologous immunization scheme.

    Conclusions:

    • Non-replicative viral vectors MVA and Ad5 expressing RABV glycoprotein are effective platforms for anti-rabies vaccines.
    • The Ad-RG vaccine candidate shows exceptional promise, achieving 100% protection in a stringent mouse model.
    • Further evaluation in target animal species is warranted to advance this vaccine candidate for rabies control.